ULBI

Business Context and Reporting Period

Company: Ultralife Batteries, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 2, 2005
Business Overview: A global provider of non-rechargeable and rechargeable batteries and power solutions for military, industrial, and consumer applications. The company operates in three segments: Non-rechargeable Batteries, Rechargeable Batteries, and Technology Contracts.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 24% ($6.8M) in Q2 and 33% ($18.5M) in the first six months compared to the prior year. This was primarily driven by a 33% drop in Non-rechargeable battery sales due to lower shipments of BA-5390 batteries to the U.S. military during a procurement transition.
• Margin Compression: Gross margins fell from 25% to 19.5% in Q2 and from 24% to 16.9% for the six-month period, attributed to lower production volumes of large cylindrical batteries.
• Operating Expenses: Operating expenses increased 17% in Q2 and 21% for the six-month period, driven by higher R&D spending and increased audit fees related to Sarbanes-Oxley compliance.
• Income Tax Provision: A significant non-cash deferred tax expense of $1,063 was recorded in Q2 due to a change in New York State income tax law, impacting the net loss significantly.
• Debt Reclassification: Due to uncertainty regarding compliance with financial covenants, $6,000 of long-term debt was reclassified as current liabilities.

Guidance, Outlook, and Risks

Management Commentary and Guidance

• 2005 Full Year Projection: Management revised full-year revenue guidance down to approximately $83 million, compared to previous guidance of $98.2 million to $108 million.
• Q3 and Q4 Outlook: Projected Q3 revenue is approximately $21 million with positive operating income. Q4 revenue is projected at $25 million with improving margins.
• Long-Term Targets: The company aims for $200 million in revenue over the next 3-4 years, with gross margins targeting 30% and operating expenses trending toward 10% of revenue at higher sales volumes.

Risks and Contingencies

• Debt Covenants: The company did not meet minimum requirements for debt-to-earnings and EBIT-to-interest ratios as of July 2, 2005. While waivers were obtained in May and August 2005, there is no assurance future waivers will be granted.
• Military Procurement: Continued uncertainty regarding the timing of BA-5390 order flow from the U.S. military remains a primary risk.
• Environmental Liability: Ongoing remediation of contaminated soil at the Newark, NY facility. Approximately $66 is reserved, with potential for additional costs.
• Supplier Risk: Prepayments of approximately $196 to Ultralife Taiwan Inc. (UTI) carry the risk of non-delivery if UTI faces financial difficulties.

Investor Verification Checklist

• Debt Covenant Compliance: Verify the status of the August 2005 amendment to the credit facility and the company's ability to meet revised financial metrics.
• BA-5390 Order Flow: Monitor announcements regarding the qualification of the Next Gen II, Phase IV award and subsequent military contract awards.
• Deferred Tax Asset: Assess the realizability of the deferred tax asset given the company's recent net losses and the impact of the NY State tax law change.
• Inventory Levels: Review inventory turnover rates, as inventory increased to $17.5M, potentially indicating overstocking in anticipation of military orders that have been delayed.
• Environmental Remediation: Track the approval of the work plan for additional sampling at the Newark facility to estimate final remediation costs.